List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 22 studies with search of: "Hemagglutinins"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
Condition: Influenza
Intervention: Biological: Influenza Vaccine, recombinant Hemagglutinin
2 Active, not recruiting Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok
Condition: Influenza
Interventions: Biological: Influenza Vaccine, recombinant hemagglutinin;   Drug: Saline salt
3 Active, not recruiting Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
Conditions: Influenza;   Pandemic Influenza
Intervention: Biological: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
4 Active, not recruiting Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
Condition: Influenza
Intervention: Biological: Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
5 Active, not recruiting Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
Condition: Influenza
Interventions: Biological: Influenza Vaccine, Recombinant Hemagglutinin;   Biological: TIV
6 Completed Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
Conditions: Influenza A Virus, H5N1 Subtype;   Influenza A Virus;   Influenzavirus A;   Orthomyxovirdae;   H5N1 Virus
Intervention: Drug: VRC-AVIDNA036-00-VP
7 Suspended Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines
Condition: Influenza Disease
Interventions: Biological: adjuvanted influenza vaccine contains the purified viral envelope-glycoproteins neuraminidase (NA) and hemagglutinin (HA);   Biological: Novartis Vaccines Trivalent Subunit Inactivated Influenza Vaccine;   Biological: Novartis Vaccines Meningococcal C Conjugate Vaccine or Novartis Vaccines Tick-borne Encephalitis Vaccine
8 Enrolling by invitation Safety and Immunogenicity of Influenza H9 Vaccine in Humans
Condition: Influenza
Interventions: Biological: H9N2 whole virus vaccine, IM, 1.5microg;   Biological: H9N2 whole virus vaccine, IM, 5microg;   Biological: H9N2 whole virus vaccine vaccine, IM, 15microg;   Biological: H9N2 whole virus vaccine, IM, 45microg;   Biological: H9N2 whole virus vaccine, alum, IM, 1.5microg;   Biological: H9N2 whole virus, alum, IM, 5microg;   Biological: H9N2 vaccine, whole virus, alum, IM, 15 microg;   Biological: H9N2 vaccine, whole virus, alum, IM, 45microg;   Biological: H9N2 virosome vaccine, IM, 1.5microg;   Biological: H9N2 virosomal vaccine, IM, 5microg;   Biological: H9N2 virosomal vaccine, IM, 15microg;   Biological: H9N2 virosomal vaccine, IM, 45microg;   Biological: H9N2 whole virus vaccine, ID, 5microg;   Biological: H9N2 whole virus vaccine, ID, 15microg
9 Active, not recruiting Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
Condition: Influenza
Interventions: Biological: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen;   Biological: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen;   Biological: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen;   Biological: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen;   Biological: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen;   Biological: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
10 Completed Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults
Condition: Influenza
Interventions: Biological: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free;   Biological: CSL Trivalent Inactivated Influenza Vaccine with Thimerosal;   Biological: Placebo with Thimerosal
11 Active, not recruiting Safety and Immunogenicity of FluBlok in Pediatrics
Condition: Influenza
Intervention: Biological: FluBlok
12 Active, not recruiting Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlØk™, To a Licensed Vaccine In Elderly Adults
Condition: Influenza
Intervention: Biological: FluBlok (influenza vaccine)
13 Enrolling by invitation Safety and Immunogenicity Study of Adenovirus-Vectored, Intranasal Pandemic Influenza Vaccine.
Condition: Pandemic Influenza
Intervention: Biological: Pandemic Influenza Vaccine
14 Completed A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza
Condition: Influenza
Interventions: Biological: AVX502;   Biological: AVX502;   Biological: AVX502;   Biological: AVX502;   Biological: AVX502;   Biological: AVX502;   Biological: AVX502;   Biological: AVX502;   Biological: Placebo;   Biological: Placebo;   Biological: Placebo;   Biological: Placebo
15 Completed Safety Study of Avian Flu Vaccine
Conditions: Influenza A Virus, H5N1 Subtype;   Influenza A Virus;   Influenzavirus A;   Orthomyxoviridae;   H5N1 Virus
Intervention: Drug: VRC-AVIDNA036-00-VP
16 Active, not recruiting A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
Condition: Influenza
Interventions: Biological: AVX502;   Biological: AVX502;   Biological: Placebo;   Biological: Placebo
17 Recruiting Phase III Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
Condition: Influenza
Interventions: Biological: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted;   Biological: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
18 Recruiting Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-Flagellin Influenza Vaccine
Condition: Influenza
Intervention: Biological: VAX125
19 Active, not recruiting Safety and Immune Response of Different Pediatric Combination Vaccines.
Conditions: Diphtheria;   Polio;   Pertussis
Interventions: Biological: DAPTACEL (DTaP);   Biological: DTaP-IPV/Hib combined;   Biological: DTaP-IPV and ActHIB;   Biological: DTaP-IPV/Hib combined
20 Recruiting Therapy for Chronic Cold Agglutinin Disease
Condition: Cold Agglutinin Disease
Interventions: Drug: Rituximab;   Drug: Fludarabine

Previous Page Studies Shown (1-20) Next Page (21-22)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services